Significance of the clinical studes in Ghana and Pobé
• Represents the first evidence that preulcerative or small-to-moderate size Buruli ulcer may be cured by chemotherapy alone.
• Is a major breakthrough in the treatment of Buruli ulcer.
Operational difficulties of treating Buruli ulcer with RIF-STR
• Daily intramuscular injection of STR for 4 to 8 weeks is too demanding operationally in rural Africa.
• The treatment also carries the risk of transmission of HIV infection. More should be learned about in vitro data against M.ulcerans
• The clinical significance of these in vitro data remains unclear.
• More phramacokinetic and pharmacodynamic studies are needed to assess usefulness of in vitro data to predict in vivo effect of antimicro-bials against M.ulcerans. • Either MXF, R207910 or LZD might be considered as a companion drug with RIF, yielding an orally administered, combined regimen for treatment of Buruli ulcer.
• Taking into account the cost, potential toxicity and availability, MXF is the only orally administered antimicrobial agent feasible to be applied as a companion drug with RIF.
Justifications to launch a clinical trial of RIF-MXF for Buruli ulcer
• RIF-MXF displays promising bactericidal activity against M.ulcerans similar to that of RIF-STR in mice.
• MXF is well tolerated for treatment of various clinical conditions.
• A number of MXF-containing combined regimens for treatment of pulmonary TB are being evaluated in Phase-2 & -3 human trials.
Current situation about fluoroquinolones in paediatric population
• Long-term (more than several weeks) applica-tion of fluoroquinolone in children and adolescents has not been approved due to concerns of potential damage to bone and cartilage growth.
• In reality, prescriptions for fluoroquinolones to treat infections in children has become increasingly prevalent.
• Ciprofloxacin has recently been approved by FDA for treatment of infections in children, and gatifloxacin has also been examined in large-scale studies of paediatric patients.
